Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Skin Cell Dip, Stem Cell Dip, Wage Token Distribution, ESG Compliance Monitoring, Operational protocol.
- Who it may be relevant to
- Registry conditions: Mobility Impairment, Clinical Workflow Optimization, Sanitation Protocol Compliance, ESG-linked Healthcare Robotics Deployment. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, Germany, Japan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
HEALTH: Humanoid Evaluation and Learning Trial in Coalition-Aligned Healthcare Settings
Overview
This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.
Detailed description
The HEALTH trial (Humanoid Evaluation and Learning Trial in Healthcare) is a coalition-aligned clinical study designed to assess the deployment of humanoid robotics in real-world care environments. Conducted across metro facilities in New York, Austin, Frankfurt, and Tokyo, the trial evaluates robotic performance in patient intake, sanitation, mobility assistance, and ESG-linked operations.
Humanoid units are enhanced through biotech integration, including skin cell regeneration dips and stem cell neural augmentation. Each unit is tracked via biometric audit scoring across five dimensions: motor function, cognitive response, ESG compliance, biotech retention, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard.
Wage tokens (HumanoidWage, HMW) are minted based on performance thresholds and distributed through smart contracts to deployed units. FX arbitrage across Tokyo and Frankfurt informs reinvestment logic and 1031 exchange-backed yield farming pools. DAO voting governs deployment, wage calibration, and protocol expansion.
This trial aims to establish scalable, transparent frameworks for humanoid integration in healthcare, anchored in coalition governance, public oversight, and metro-ready infrastructure.
Interventions
- Biological Skin Cell Dip
Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration. - Biological Stem Cell Dip
iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning. - Other Wage Token Distribution
HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion. - Behavioral ESG Compliance Monitoring, Operational protocol
Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.
Primary outcome measures
- Biometric Audit Score ≥85 Across Five Performance Dimensions [Time frame: Measured at Day 30 Post-Deployment]
Secondary outcome measures (3)
- ESG Audit Compliance Score ≥90 [Time frame: Humanoid units are evaluated for ESG-linked performance including energy usage, sanitation protocol adherence, and carbon offset metrics. Scores are published to the coalition dashboard and notarized via SHA-256. Units scoring ≥90 contribute to DAO-backe]
- Wage Token Distribution Volume per Unit [Time frame: Continuous Monitoring Over 90 Days]
- Clinical Workflow Efficiency Increase ≥15% [Time frame: Measured at Day 90 Post-Deployment]
Eligibility criteria
Inclusion criteria
\- Age 18-75 years
Able to provide informed consent
Facility staff, clinical auditors, ESG observers, or coalition stakeholders
Willing to interact with humanoid robotics in clinical workflows
Available for biometric feedback and observational logging over 90 days
Exclusion criteria
\- Cognitive impairment preventing informed consent
Active infectious disease requiring isolation
Prior adverse reaction to biotech-enhanced robotics
Involvement in conflicting clinical trials
Inability to comply with protocol procedures or coalition transparency requirements
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Health services research
Study locations
United States · 2 centers
- Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016 — New York
- Coalition Retrofit Clinic - Austin, TX — Austin
Germany · 1 center
- ESG Compliance Lab — Frankfurt
Japan · 1 center
- Public Interface Pilot — Tokyo
Identifiers
NCT: NCT07214896 · TRU-HUM-CLIN-2025-PRS